

Abreu & Stone et. al.

A Phase 1b/2a Clinical Trial of Dantrolene Sodium in Patients with Wolfram Syndrome

Damien Abreu BS^{1,2†}, Stephen I Stone, MD^{3†}, Toni Pearson MD⁴, Robert Bucelli MD PhD⁴, Ashley N Simpson RN BSN⁵, Stacy Hurst RN BSN¹, Cris M Brown BA¹, Kelly Kries BA¹, Hongjie Gu MS⁶, James Hoekel OD⁷, Lawrence Tyachsen MD⁷, Gregory P. Van Stavern MD⁷, Neil H White MD³, Bess A Marshall MD³, Tamara Hershey PhD⁸, and Fumihiko Urano MD PhD^{1,9¶}

[†]These authors contributed equally to this work. [¶]Denotes corresponding author: urano@wustl.edu

¹Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, ²Medical Scientist Training Program, ³Department of Pediatrics, Division of Endocrinology and Diabetes, ⁴Department of Neurology, ⁵Center for Clinical Studies, ⁶Division of Biostatistics, ⁷Department of Ophthalmology and Visual Sciences, ⁸Departments of Psychiatry and Radiology, ⁹Department of Pathology and Immunology
Washington University School of Medicine, St. Louis MO 63110, USA

Abstract

Background. Wolfram syndrome is a rare endoplasmic reticulum disorder characterized by insulin-dependent diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration. Although there is currently no treatment to delay, halt, or reverse the progression of Wolfram syndrome, preclinical studies in cell and rodent models suggest that therapeutic strategies targeting endoplasmic reticulum calcium homeostasis, including dantrolene sodium, may be beneficial.

Methods: Based on the results from preclinical studies on dantrolene sodium and ongoing longitudinal studies, our group put together the first-ever clinical trial in pediatric and adult patients with Wolfram syndrome. An open-label phase 1b/2a trial design was chosen. The primary objective of the study was to assess the safety and tolerability of dantrolene sodium in adult and pediatric patients with Wolfram syndrome. Secondary objectives were to evaluate the efficacy of dantrolene sodium on residual pancreatic β -cell functions, visual acuity, quality of life measures related to vision, and neurological functions.

Results: The results indicate that dantrolene sodium is well tolerated by patients with Wolfram syndrome. Although the study was small, a select few patients seemed to have improvements in β -cell function, which might correlate with a positive trend in other outcome measures, including visual acuity and neurological functions.

Conclusion. This study justifies further investigation into using dantrolene sodium and other small molecules targeting the endoplasmic reticulum for the treatment of Wolfram syndrome.

Abreu & Stone et. al.

32 **Trial registration**

33 ClinicalTrials.gov Identifier NCT02829268

34

35 **Conflict of interest statement**

36 F. Urano received research funding from Eli Lilly, Ono Pharmaceuticals, and Amaranthus

37 BioScience for the development of MANF-based regenerative therapy for Wolfram syndrome,

38 optic nerve atrophy, and diabetes. F. Urano received chemical compounds from Amylyx

39 Pharmaceuticals, Mitochon Pharmaceuticals, Aetas Pharma, and National Center for Advancing

40 Translational Sciences for the development small molecule-based therapies for ER stress-related

41 disorders, including Wolfram syndrome. F. Urano is an inventor of two patents related to the

42 treatment of Wolfram syndrome, US 9,891,231 B2 SOLUBLE MANF IN PANCREATIC BETA

43 CELL DISORDERS and US 10,441,574, B2 TREATMENT FOR WOLFRAM

44 SYNDROME AND OTHER ER STRESS DISORDERS. F. Urano is a founder of

45 CURE4WOLFRAM, INC.

46

47 **Role of funding source**

48 The funding source had no role in the design of this study, during its execution, analyses,

49 interpretation of the data, or decision to submit results.

50

Abreu & Stone et. al.

51 **Key Points**

52 **Question:** Is dantrolene sodium safe and effective for the treatment of adult and pediatric
53 patients with Wolfram syndrome?

54 **Findings:** The results of this open-label clinical trial show that dantrolene sodium is well
55 tolerated by patients with Wolfram syndrome. Although the study was small, a select few
56 patients seemed to have improvements in β -cell function, which might correlate with a positive
57 trend in other outcome measures, including visual acuity and neurological functions.

58 **Meaning:** Dantrolene sodium is well tolerated by patients with Wolfram syndrome. Some
59 patients may experience an increase in β cell function when taking dantrolene.

60

Abreu & Stone et. al.

61 **Abstract**

62 **Importance:** Wolfram syndrome is a rare endoplasmic reticulum disorder characterized by
63 insulin-dependent diabetes mellitus, optic nerve atrophy, and progressive neurodegeneration.
64 Although there is currently no treatment to delay, halt, or reverse the progression of Wolfram
65 syndrome, preclinical studies in cell and rodent models suggest that targeting endoplasmic
66 reticulum calcium homeostasis, including dantrolene sodium, is an emerging therapeutic
67 strategy.

68 **Objective:** The primary objective of the study was to assess the safety and tolerability of
69 dantrolene sodium in adult and pediatric subjects with Wolfram syndrome. Secondary objectives
70 were to evaluate the efficacy of dantrolene sodium on residual pancreatic β -cell functions, visual
71 acuity, quality of life measures related to vision, and neurological functions.

72 **Design:** Open-label phase 1b/2a trial of dantrolene sodium over a 6-month treatment period.

73 **Setting:** Single site, academic medical center.

74 **Participants:** Adult and pediatric subjects with a genetically confirmed diagnosis of Wolfram
75 syndrome.

76 **Interventions:** All subjects received increasing doses of dantrolene sodium.

77 **Main Outcomes and Measures:** The safety and tolerability of dantrolene sodium administered
78 orally at the upper end of therapeutic dose range for 6 months, and the efficacy of dantrolene
79 sodium on residual pancreatic β -cell functions using a mixed-meal tolerance test, visual acuity
80 using LogMar scores, quality of life measures related to vision using Visual Functioning
81 Questionnaire – 25, and neurological functions using the Wolfram Unified Rating Scale (WURS)
82 and standard neurological assessments.

Abreu & Stone et. al.

83 **Results:** The results indicate that dantrolene sodium is well tolerated by subjects with Wolfram
84 syndrome. Although the study was small, a select few subjects seemed to have improvements in
85 β -cell function, which might be correlated with a positive trend in visual acuity.

86 **Conclusions and Relevance:** This study justifies further investigation into using dantrolene
87 sodium and other small molecules targeting the endoplasmic reticulum for the treatment of
88 Wolfram syndrome.

89 **Trial Registration:** Registered with clinicaltrials.gov, NCT02829268,
90 (<https://clinicaltrials.gov/ct2/show/NCT02829268?term=NCT02829268&draw=2&rank=1>)

Abreu & Stone et. al.

91 **Introduction**

92 Wolfram syndrome is an ultra-rare, progressive neurodegenerative disorder characterized by
93 juvenile-onset insulin-requiring diabetes mellitus and optic nerve atrophy^{1,2}. Other clinical
94 manifestations of Wolfram syndrome include diabetes insipidus, deafness, neurogenic bladder,
95 and ataxia. Most individuals with Wolfram syndrome have a shortened lifespan due to severe
96 neurological disabilities caused by brain stem and cerebellar atrophy³. There has yet to be a
97 treatment devised which has been shown to provide a cure or slow the insidious progression of
98 this disease. As a result, patients with Wolfram syndrome are currently only offered therapies
99 aimed at treated each aspect of the disease individually.

100

101 Since the discovery of *WFS1* as the causative locus for most cases of Wolfram syndrome,
102 research efforts have sought to understand the underlying etiology of this disorder. Our current
103 understanding is that Wolfram syndrome is a prototype of endoplasmic reticulum (ER) disease in
104 humans⁴. *WFS1* is a multi-pass ER transmembrane protein with an established role in the
105 negative regulation of ER stress and the maintenance of cellular calcium homeostasis^{5,6}. While
106 the molecular details of *WFS1* function require further study, it is clear that pancreatic β -cells
107 and neurons are particularly affected by, and perhaps especially sensitive to, disease-causing
108 *WFS1* genetic variants. Indeed, previous reports from our lab identified calcium dyshomeostasis
109 as a key mechanism underlying pancreatic β -cell and neuronal cell death in the context of *WFS1*
110 depletion⁷⁻⁹. These pre-clinical studies led to identify dantrolene sodium as a potential
111 therapeutic candidate for restoring ER calcium homeostasis and mitigating the progression of
112 Wolfram syndrome.

113

Abreu & Stone et. al.

114 Dantrolene sodium is a hydantoin derivative skeletal muscle relaxant whose mechanism of action
115 revolves around the inhibition of ryanodine receptors (RyR) on the ER¹⁰⁻¹². Although the
116 mechanism of action of dantrolene remains unclear, its effects are well-documented. Dantrolene
117 inhibits ER calcium efflux through RyR, thereby reducing cytosolic calcium and preserving ER
118 calcium¹³. The primary indication for dantrolene is in the treatment of malignant hyperthermia,
119 which can be an adverse reaction to general anesthesia and is FDA approved for use in both
120 adults and children. Dantrolene has also been used off-label for the treatments of spasticity
121 disorders and cerebral vasospasm^{14,15}. Interestingly, recent studies have proposed a potential role
122 for dantrolene sodium as a treatment for neurodegenerative disorders such as Huntington's
123 disease¹⁶, spinocerebellar ataxia^{17,18}, and Alzheimer's disease^{19,20}, where ER calcium may play
124 a pivotal role in disease pathogenesis.

125
126 Murine and induced pluripotent stem cell (iPSC) models of Wolfram syndrome were treated with
127 dantrolene sodium to determine the feasibility of a clinical trial⁸. After receiving promising
128 results from these pre-clinical studies, our group put together the first ever clinical trial in
129 subjects with Wolfram syndrome. Our research team was particularly sensitive to the unique
130 challenges of performing a clinical trial for a disease as rare as Wolfram syndrome²¹. These
131 challenges include the small numbers of subjects available to study and the vast heterogeneity of
132 symptoms exhibited by patients with Wolfram syndrome²². Multiple stakeholders were involved
133 in the design of this clinical trial including I-TRAK (a natural history study of neurodegeneration
134 in early Wolfram syndrome, NCT03951298) and various Wolfram syndrome patient/parent
135 advocacy groups as they would be likely sources for recruitment. After these collaborations, an
136 open-label phase 1b/2a trial design was chosen. The primary endpoint of the study was to assess

Abreu & Stone et. al.

137 the safety and tolerability of dantrolene sodium in adult and pediatric subjects with Wolfram
138 syndrome. Secondary objectives were also to assess the effect of dantrolene sodium on residual
139 pancreatic β -cell function, visual acuity, neurological function and quality of life measures.

Abreu & Stone et. al.

140 **Results**

141 *Trial population*

142 A total of 22 subjects (6–32 years old) with a genetically confirmed diagnosis of Wolfram
143 syndrome, were screened for enrollment in this study (Figure 1B). Of this group, 21 qualified for
144 baseline laboratory and quality of life assessments in order to begin the run-in regimen of oral
145 dantrolene parallel to ongoing maintenance medications. Two subjects (11% of qualified
146 population) had to be excluded before the 6-month assessment of study outcome measures on
147 dantrolene treatment due to loss to follow-up or personal reasons. The baseline demographic and
148 clinical characteristics of the 19 subjects that completed the trial are shown in Table 1. Subject-
149 specific *WFS1* mutations and clinical data are summarized in Supplementary Table S1. At
150 enrollment 100% of subjects carried a diagnosis of diabetes mellitus. However, only 63% of
151 pediatric subjects and 100% of adult subjects carried a diagnosis of optic atrophy. This pattern is
152 consistent with the documented natural history of Wolfram syndrome, where juvenile-onset
153 diabetes mellitus typically manifests within the first decade, followed by optic atrophy in the
154 second decade of life^{3,23,24}.

156 *Safety outcomes*

157 Dantrolene was well-tolerated among pediatric subjects at a final daily dose between 0.5 mg/kg
158 and 2.0 mg/kg, with a maximum daily dose of 100 mg. The mean final daily dose in the pediatric
159 subjects was 1.25 mg/kg/day (Figure 1C). Adults subjects tolerated dantrolene well between 50
160 mg to 100 mg daily. 5, 4, and 2 subjects tolerated 50, 75, and 100 mg of dantrolene respectively.
161 This resulted in a mean dose of 68.2 mg daily (Figure 1D). These dosing ranges closely
162 approximated therapeutic ranges for dantrolene when used to treat spasticity²⁵.

Abreu & Stone et. al.

163
164 Adverse events were stratified into three categories based on their likelihood of being attributed
165 to the study drug. These categories included adverse events attributed directly to dantrolene,
166 events known to occur commonly in patients with Wolfram syndrome, and non-specific events
167 not easily attributed to dantrolene or Wolfram syndrome. The most common adverse dantrolene
168 related events observed in pediatric and adult subjects were mild fatigue and diarrhea. The most
169 common Wolfram syndrome related events were mild hypoglycemia, and headaches. These
170 symptoms affected at least 25% of the total study population (Table 2). Hepatotoxicity and
171 weakness, the most serious known side effects of dantrolene, were not very prevalent in our
172 study population. Elevated liver enzymes were observed in 2 subjects (11% of total population)
173 and weakness was self-reported by 4 subjects (21% of total population). Quantitative
174 assessments of strength prior to and at each subsequent trial visit after dantrolene administration
175 showed no significant loss in grip strength during 6-months of dantrolene treatment
176 (Supplementary Figure 1). No clinically significant changes in laboratory measures or in findings
177 from physical examinations were noted during enrollment in this study. No significant EKG
178 changes were observed in subjects during the run-in period or thereafter. Additionally, no subject
179 discontinued the trial regimen due to adverse effects.

180

181 ***Secondary outcomes***

182 *-Markers of β -cell function*

183 To assess the effect of dantrolene on glycemia and remaining β -cell function, HbA1c and 30-
184 minute mixed-meal stimulated C-peptide were monitored at baseline and after 6-months of
185 dantrolene treatment (Figure 1A). Mean HbA1c across all subjects remained stable between

Abreu & Stone et. al.

186 dantrolene initiation and after 6-months of treatment (7.4 ± 0.2 %, p -value 0.63). Subgroup
187 analyses of adult and pediatric subjects also demonstrated no significant change in HbA1c (7.4
188 ± 0.2 %) (Figure 2A). Mean fasting C-peptide levels of the total study cohort also remained
189 stable during this period (0.27 ± 0.07 ng/mL at 6-months of treatment compared to 0.27 ± 0.06
190 ng/mL at baseline, p -value 0.95). At the conclusion of the study, mean stimulated C-peptide
191 levels were not significantly higher compared to the pre-treatment baseline (0.64 ± 0.14 ng/mL
192 after 6-months of treatment compared to 0.52 ± 0.10 ng/mL at baseline, p -value 0.14) (Figure
193 2B). Supplementary Figure 2 demonstrates subject specific change in fasting and stimulated C-
194 peptide over the 6-month study period. When looking at all subjects, Δ C-peptide (the change in
195 C-peptide between 0 and 30 minutes) was not significantly increased. Mean Δ C-peptide was 0.37
196 ± 0.07 ng/mL after 6-months of treatment, compared to 0.25 ± 0.04 ng/mL at baseline (p -value
197 0.18) (Figure 3A and Supplementary Table S2).

198
199 Additional markers of β -cell function were performed including measuring proinsulin along with
200 C-peptide during the mixed meal tolerance testing. Insulinogenic index ²⁶ and area under the
201 curve (AUC) C-peptide / AUC Glucose ²⁷ were calculated for each study subject. No significant
202 differences were found in any of these categories (Supplementary Table S2).

203
204 *-Subgroup analyses*

205 Additional subgroup analysis was performed in the study population to determine if there was
206 subset of subjects who had the most beneficial response to dantrolene. Our hypothesis was that
207 subjects who possessed the greatest degree of β cell function at baseline, would have the greatest
208 glycemic benefit from dantrolene. Therefore, we examined the change in Δ C-peptide ($\Delta\Delta$ C-

Abreu & Stone et. al.

209 peptide) over the course of the study to approximate changes in β cell responsiveness. $\Delta\Delta$ C-
210 peptide was calculated by subtracting the Δ C-peptide at baseline from the Δ C-peptide at 6-
211 months. In order to test our hypothesis, we divided the subjects based on increasing cutoffs of
212 $\Delta\Delta$ C-peptide (0.05, 0.1, and 0.2 ng/mL). We noted that 8 subjects had a $\Delta\Delta$ C-peptide \geq 0.05
213 ng/mL, 5 subjects had a $\Delta\Delta$ C-peptide \geq 0.1 ng/mL, and 4 subjects had a $\Delta\Delta$ C-peptide \geq 0.2
214 ng/mL. The remaining 6 subjects had a $\Delta\Delta$ C-peptide $<$ 0.05 ng/mL or were missing data
215 necessary for calculation of $\Delta\Delta$ C-peptide (Figure 3A). Review of these data suggested that our
216 hypothesis was correct, as subjects with higher Δ C-peptide to begin with, tended to have a higher
217 Δ C-peptide at 6 months and higher slope ($\Delta\Delta$ C-peptide). To further test this relationship, we
218 performed linear regression analysis demonstrating a statistically significant (R^2 0.439, p -value
219 0.004) positive relationship between baseline Δ C-peptide, and ($\Delta\Delta$ C-peptide) (Figure 3B). A
220 histogram was created to visualize the distribution of $\Delta\Delta$ C-peptide amongst the study subjects
221 (Figure 3C). The 0.05, 0.1, and 0.2 ng/mL cutoffs were superimposed upon this the linear
222 regression and histograms. Based on previous literature ^{28,29}, we decided that the cutoff of a
223 $\Delta\Delta$ C-peptide \geq 0.1 ng/mL is likely to be of clinical significance, for subjects with Wolfram
224 syndrome. This fit the overall distribution of data, as 5 subjects (subject ID #4, 8, 10, 17, and
225 22), met this criterion. They represented 26.3% of the total study population. These subjects
226 included 3 adult and 2 pediatric individuals. The $\Delta\Delta$ C-peptide \geq 0.1 ng/mL cutoff is henceforth
227 used to classify subjects as responders versus non-responders.

228
229 As our hypothesis is that subjects with increased β cell function had a more robust response to
230 dantrolene, we set out to determine if any baseline measurement had predictive value. This could
231 help clinicians, caring for patients with Wolfram, determine if dantrolene could be beneficial.

Abreu & Stone et. al.

232 Therefore basal, stimulated, and Δ C-peptide data collected from subjects prior to starting
233 dantrolene were analyzed to determine which of these criteria could best be used. Histograms
234 and receiver-operator-characteristic (ROC) curves were created based on these data. A positive
235 control using $\Delta\Delta$ C-peptide which, by design, demonstrated 100% sensitivity and specificity
236 using a $\Delta\Delta$ C-peptide value ≥ 0.12 ng/mL was also created (Supplementary Figure 3D,H).
237 Baseline measurements of β -cell function had a modest predictive value. Unstimulated (Basal)
238 C-peptide had the highest area under the curve (AUC), demonstrating a peak of 60% sensitivity,
239 and 100% specificity when using a cutoff of 0.38 ng/mL. Similarly, stimulated C-peptide
240 demonstrated 60% sensitivity and 100% specificity when using a cutoff of 0.725 ng/mL. Δ C-
241 peptide had the lowest AUC, demonstrating 40% sensitivity and 100% specificity when using a
242 cutoff of 0.44 ng/mL (Supplementary Figure 3A-C, E-G; Supplementary Table S3)

243
244 There were no significant differences between responders and non-responders in terms of HbA1c
245 at the beginning (7.1 ± 0.2 % and 7.5 ± 0.2 % respectively, p -value 0.49) of the study and after 6-
246 months of treatment (7.1 ± 0.3 % and 7.6 ± 0.3 % respectively, p -value 0.42). Prior to treatment
247 with dantrolene, responder subjects had higher fasting C-peptide compared to non-responders
248 (0.47 ± 0.17 ng/dL compared to 0.18 ± 0.03 ng/dL, p -value 0.03). By design, responder subjects
249 demonstrated statistically significant increases in fasting C-peptide (0.53 ± 0.17 ng/dL to $0.15 \pm$
250 0.006 ng/dL), stimulated C-peptide (1.20 ± 0.33 ng/dL to 0.38 ± 0.05 ng/dL p -value 0.003), and
251 Δ C-peptide (0.67 ± 0.17 ng/dL to 0.23 ± 0.02 ng/dL p -value 0.002) after the 6-month treatment
252 period. Similar patterns were seen in between responders and non-responders when measuring
253 proinsulin, insulinogenic index, and AUC C-peptide / AUC Glucose. C-peptide to glucose ratio

Abreu & Stone et. al.

254 seemed to be elevated in the pediatric and responder groups compared to adults and non-
255 responders respectively (Supplementary Figure 4, Supplementary Table S4).

256

257 *-Markers of visual acuity*

258 To evaluate the effect of dantrolene treatment on visual acuity and vision-related quality of life,
259 participants underwent ophthalmologic examination at screening, and at baseline, and after 6
260 months of dantrolene treatment. No significant changes in visual acuity were observed across
261 subjects or age groups as a function of dantrolene treatment (Figure 2C, Supplementary Table
262 S2). Of note, subject 12 had a LogMAR = 3 throughout the study period, which equates to
263 functional blindness. As a result, subject 12's data was excluded from analysis. Supplementary
264 Figure 5 demonstrates the LogMAR data including subject 12. Subgroup analyses did not
265 identify any significant differences between adult and pediatric subjects or subjects deemed to be
266 non-responders or responders. Correspondingly, subjects reported no significant improvements
267 in vision-related quality of life as measured by the NEIVFQ-25 (Supplementary Table S5).

268

269 Linear regression analysis was performed comparing $\Delta\Delta$ C-peptide to LogMAR. This resulted in
270 a slight, but statistically significant negative correlation (R^2 0.136, p -value 0.023)
271 (Supplementary Figure 6A).

272

273 *-Disease severity and quality of life*

274 Overall disease severity was assessed in subjects prior to, and 6-months after starting dantrolene
275 treatment via WURS assessment³⁰. There were no differences in total WURS disease severity,
276 or mean physician rated physical exam scores across the 6 months of the study. Subgroup

Abreu & Stone et. al.

277 analysis noted that pediatric subjects demonstrated statistically insignificant lower physician
278 rated WURS (3.1 ± 1.3 at baseline and 3.1 ± 1.2 after 6-months) (p -value 1.00) than adult
279 subjects (7.6 ± 1.8 at baseline and 8.8 ± 2.7 after 6-months) (p -value 0.71) (p -value 0.09 and 0.11
280 at baseline and 6-months respectively when comparing pediatric to adult subjects). Subjects
281 deemed to be responders also demonstrated statistically insignificant lower physician rated
282 WURS scores when comparing baseline (4.2 ± 1.6) and 6-months (3.2 ± 1.2) (p -value 0.62).
283 Non-responders saw a statistically insignificant increase in physician rated WURS scores when
284 comparing baseline (6.3 ± 1.6) to 6-months of treatment (7.5 ± 2.3) (p -value 0.67) (p -value 0.48
285 and 0.28 at baseline and 6-months respectively when comparing non-responder to responder
286 subjects) (Figure 2, and Supplementary Tables S2 and S4). Similarly, pediatric subjects
287 displayed no significant changes in physical or psychosocial health domains as measured by the
288 PedsQL questionnaire between screening and 6 months of dantrolene therapy (Supplementary
289 Table S6) and adult subjects did not show differences in physical or mental health metrics when
290 assessed by the SF-36v (Supplementary Table S7).

291
292 Similar to the LogMAR data, linear regression analysis was performed correlating $\Delta\Delta$ C-peptide
293 to Total WURS and physician rated WURS. These regression plots appeared to demonstrate a
294 negative correlation, but did not reach statistical significance (R^2 0.085, p -value 0.117 and R^2
295 0.021, p -value 0.444 for total WURS and physician rated WURS respectively) (Supplementary
296 Figure 6 B-C).

297

Abreu & Stone et. al.

298 **Discussion**

299 In this study, we evaluate the safety and tolerability of dantrolene sodium as a therapeutic
300 approach for Wolfram syndrome. Our preclinical studies show that dantrolene improves β -cell
301 and neuronal cell survival in mouse and patient iPSC models of this disease⁸. To translate these
302 findings to humans, we conducted the first clinical trial in pediatric and adult subjects with
303 Wolfram syndrome in a 6-month study of dantrolene sodium (NCT02829268). We identified a
304 tolerable range of oral dantrolene dosing of 0.5mg/kg/day to 2mg/kg/day for pediatric subjects
305 and 50mg/day to 100mg/day for adults. Overall, dantrolene was very well tolerated, and aside
306 from mild fatigue and diarrhea, no clinically significant adverse events were reported.

307
308 Admittedly, this proof of concept study ran into many of the same issues that plague early
309 clinical trials for rare diseases²¹. As the incidence of Wolfram syndrome is so rare, it is difficult
310 to recruit a large enough sample size in order to detect a statistically significant difference in
311 secondary measures of β -cell function, visual acuity, or quality of life. In order to aid with
312 recruitment, our study team collaborated with existing natural history studies and patient/parent
313 organizations. Particularly, patient/parent organizations expressed a strong desire for a potential
314 therapeutic option, as there are currently no approved treatments aimed at slowing the
315 progression of Wolfram syndrome. Through the design of the study, potential study subjects
316 lobbied strongly against a blinded or placebo-controlled study design. This helped inform our
317 decision toward an open-label phase 1b/2a design, as a positive outcome would clear a path for
318 more widespread adoption of a drug aimed at slowing the progression of Wolfram syndrome that
319 is at least proven to be safe, if not necessarily effective in all individuals. The final challenge
320 facing this study is the vast clinical heterogeneity seen in the spectrum of individuals with

Abreu & Stone et. al.

321 Wolfram syndrome ³¹. Independent of age, some individuals are more severely affected or
322 progress more rapidly than others. Our hypothesis is that these differences may be based on the
323 severity of the *WFS1* gene variants. For example, individuals with missense mutations, may have
324 a less severe course compared to large deletions or non-sense mutations. This clinically and
325 genetically heterogeneous population makes it more challenging to infer cause and effect
326 relationships when studying a potential drug. As a result, our strategy has been to target the
327 underlying cellular defect (ER calcium depletion) that is unified amongst all patients with
328 Wolfram syndrome ³².

329
330 With the above challenges in mind, there remain many shortcomings of this study. As it is an
331 uncontrolled study, certain parameters measured are susceptible to confounding by the placebo
332 effect. Due to the small sample sizes there were no statistically significant differences in β -cell
333 function or disease severity. For these reasons, this study does not posit that dantrolene improves
334 β -cell function or disease severity. Instead, it identifies safe doses for treatment of adult and
335 pediatric subjects with Wolfram syndrome, highlights the side effect profile of dantrolene in this
336 population and argues that further investigation of dantrolene, or investigational agents with a
337 similar mechanism of action, are warranted in a randomized, double-blind, placebo-controlled
338 study. With this caveat in mind, this study also suggests that dantrolene requires further
339 investigation in the context of β -cell function and neurodegeneration.

340
341 Perhaps the most salient question arising from this study is whether dantrolene improves human
342 β -cell function in Wolfram syndrome. Mean stimulated C-peptide was not significantly different
343 when looking at all subjects. However, parsing subjects by age reveals that pediatric subjects had

Abreu & Stone et. al.

344 a statistically insignificant increase in C-peptide. Subgroup analyses, suggests that subjects with
345 better baseline β -cell function (earlier on in the progression of the disease and β -cell loss) may
346 have the most benefit from dantrolene sodium (Figure 3B). Interestingly, linear regression
347 analysis also demonstrated that subjects with the greatest increase in β -cell function tended to
348 have improved visual acuity and less severe disease (Supplementary Figure 6A). These data
349 suggest that the greatest beneficiaries of dantrolene treatment may be newly diagnosed pediatric
350 subjects who retain a significant degree of β -cell function. The ROC analysis (Supplementary
351 Figure 3) suggests that having a fasting C-peptide > 0.38 ng/mL, can help predict if a subject will
352 have an greater than 0.1 ng/mL increase Δ C-peptide over 6 months of dantrolene treatment.
353 While a controlled human study is required to assess dantrolene's efficacy at improving β -cell
354 function, pediatric subjects in our study started to exhibit a trend towards higher stimulated C-
355 peptide levels after 6-months of sustained dantrolene treatment. Adult subjects, in contrast, show
356 a negligible increase in mean stimulated C-peptide levels throughout their duration of dantrolene
357 treatment. These data suggest that dantrolene may be more effective in pediatric subjects,
358 possibly because these subjects have a larger surviving subpopulation of functional β -cells
359 during this initial phase of their disease process. Evidently, adult subjects also secrete very low
360 levels of insulin, but dantrolene did not seem to significantly enhance β -cell function in this
361 group.

362
363 The significance of these small elevations in C-peptide is quite interesting when comparing
364 Wolfram syndrome to type 1 diabetes. Recently, there has been a growing body of literature
365 suggesting that there is clinical benefit from a very small degree of residual β -cell function.
366 Oram and colleagues published a population-based study in the United Kingdom, demonstrating

Abreu & Stone et. al.

367 that 8% of subjects had a urinary C-peptide-to-creatinine ratio ≥ 0.2 nmol/mmol²⁹. This study
368 and another follow-up study in 2019 demonstrated that this persistent micro-secretion of C-
369 peptide is associated with fewer complications of diabetes and less hypoglycemia²⁸. Contrasting
370 these populations, subjects with Wolfram syndrome tend to have much higher C-peptide
371 compared to type 1 diabetes. Notably the preserved C-peptide group in the 2019 study had a
372 mean stimulated C-peptide of 114 pmol/L (0.3443 ng/mL). This is compared to a mean
373 stimulated C-peptide of 0.52 ng/mL (205 pmol/L) in our study population with Wolfram
374 syndrome. These data suggest that small, statistically insignificant, increases in C-peptide may
375 be clinically significant. Anecdotally, some of the study investigators noticed that the subject's
376 insulin needs decreased during the study, but this was not systematically evaluated in this study.
377 Additionally, many subjects wearing a continuous glucose monitors noticed more stable
378 glycemic patterns. As a result, we suggest that future studies of dantrolene or similar agents track
379 changes in total daily insulin dose (with percentage basal versus bolus) and analyze continuous
380 glucose monitor tracings (*i.e.* time-in-range, time-in-hypoglycemia, and standard deviation).

381
382 Similar to β -cell function, over 6 months of treatment with dantrolene sodium there were no
383 significant differences in markers of visual acuity. Markers of disease severity including WURS
384 score and other pediatric and adult quality of life measures did not significantly change over 6
385 months of treatment with dantrolene sodium. However, we noted that pediatric subjects tended to
386 have lower physician rated WURS scores compared to their adult counterparts.

387

Abreu & Stone et. al.

388 We postulate that efficacy of dantrolene may be linked to the nature of the *WFS1* mutations in
389 the individual subjects. Over time, and with further experience with dantrolene, perhaps
390 dantrolene can be part of a personalized medicine approach for patients with Wolfram syndrome.

391
392 In summary, this study suggests that dantrolene sodium is safely tolerated by subjects with
393 Wolfram syndrome. Although the study was small, a select few subjects seemed to have
394 improvements in β -cell function. Therefore, this study justifies further investigation into using
395 dantrolene sodium and other ER-calcium stabilizers for the treatment of Wolfram syndrome.

396

397

Abreu & Stone et. al.

398 **Methods**

399 Study approval

400 Subjects, and their parent or legal guardian, as appropriate, provided written, informed consent
401 before participating in this study, which was approved by the Human Research Protection Office
402 at Washington University School of Medicine in St. Louis, MO (IRB ID #201607006).

403

404 Trial participants

405 Subjects who met all of the following criteria were eligible for enrolment:

406 1. A definitive diagnosis of Wolfram syndrome, as determined by the following:

407 a. Documented functionally relevant recessive mutations on both alleles of the *WFS1* gene
408 or,

409 b. A dominant mutation on one allele of the *WFS1* gene based on historical test results (if
410 available) or from a qualified laboratory at screening.

411 2. The subject is at least 5 years of age (biological age) at the time of written informed
412 consent.

413 3. The subject, subject's parent(s), or legally authorized guardian(s) must have voluntarily
414 signed an Institutional Review Board/Independent Ethics Committee-approved informed consent
415 form after all relevant aspects of the study have been explained and discussed with the subject.
416 The guardians' consent and subject's assent, as relevant, must be obtained.

417

418 Study protocol

419 Dantrolene sodium was dispensed to the study subjects via the Washington University's clinical
420 trials pharmacy. Subjects were instructed to take the dantrolene by mouth. Subjects enrolled in

Abreu & Stone et. al.

421 this study underwent a run-in period for dose maximization (Figure 1A). Adult subjects were
422 started on up to 25 mg dantrolene daily for seven days, then doubled in dose on a weekly basis
423 up to a maximum of 200mg dantrolene daily. Pediatric subjects (< 18-years old) were started on
424 up to 0.5 mg/kg dantrolene daily (maximum 25 mg) for seven days, then doubled in dose on a
425 weekly basis up to a maximum of 2mg/kg dantrolene daily (maximum 200 mg), with no dose
426 change if weight fell within $\pm 3\%$ of the original dosing weight. Dosing calendars were
427 maintained by the study subjects to ensure adherence to the study drug.

428

429 Safety assessment and outcomes measures

430 Baseline screening procedures included complete physical exam, standard clinical laboratory
431 tests (serum chemistry, liver function tests, hematology, and urinalysis), and 12-lead ECG.
432 Subjects underwent formal visual acuity testing by the co-authors of the study who are either
433 optometrists or ophthalmologists. At baseline, each subject underwent the Wolfram Unified
434 Rating Scale (WURS) ³⁰. The 30-minute mixed meal tolerance test was performed to assess
435 base-line β cell functions as described before ²⁴. The mixed meal consisted of 6 ml/kg (maximum
436 360 ml) of Boost® (Nestle) consumed over a maximum of 5 minutes. After the overnight
437 fasting, blood for glucose and C-peptide measurement was drawn at time 0 (fasting) and 30
438 minutes after the Boost. If a subject's fasting glucose exceeded 250 mg/dL, the test was not
439 performed, but fasting glucose and C-peptide were obtained. An ECG was performed before and
440 4-hours after the first dose of dantrolene was administered during the run-in period, then again at
441 2-months and 6-months. Best-corrected visual acuity was assessed by Snellen optotype and
442 converted to LogMar score ³³. Vision-related quality of life was assessed in all subjects at
443 screening and after 6 months of dantrolene by the National Eye Institute's 25-item Visual

Abreu & Stone et. al.

444 Function Questionnaire (VFQ-25)³⁴. Functional activities of daily living were assessed in
445 pediatric subjects by the Pediatric Quality of Life Inventory (PedsQL) (<https://www.pedsql.org/>)
446 ³⁵, while the SF-36v2 (<https://www.optum.com/>) was used to measure self-reported functional
447 health and well-being of adults at baseline and after 6-months of dantrolene therapy ³⁶. If no
448 safety concerns were identified at screening, subjects began the 3-week dose maximization
449 period of dantrolene sodium. All baseline screening procedures were repeated again at 6-months
450 of treatment to ensure subject safety and assess dantrolene tolerability. Grip strength was
451 measured at each visit bilaterally using a digital hand dynamometer (CAMRY). A final safety
452 follow-up visit was conducted at 28 days (+/- 7 days) after the last outcome measure evaluation
453 in order to collect additional information on adverse events, concomitant medications, therapies
454 and procedures. For subjects who discontinued the study prior to the first outcomes measures
455 evaluation, safety follow-up visit was conducted within 28 days (+/- 7 days) after the last
456 administration of dantrolene sodium.

457

458 Statistics

459 Secondary outcome measures (HbA1c, Glucose, C-peptide, Proinsulin, Insulinogenic Index,
460 AUC C-peptide/ AUC Glucose, LogMAR, and WURS) were reported with the mean result \pm the
461 standard error of the mean (SEM). T-tests were performed on these secondary outcome measures
462 when comparing the same group using scipy (<https://www.scipy.org>) and pandas
463 (<https://pandas.pydata.org/index.html>) programming libraries. Paired t-tests were used when
464 comparing the same group (all-subjects, adults, pediatrics, non-responders, responders) at 0 and
465 6 months. Linear regression analyses (including R^2 and p -values) were constructed using the
466 ordinary least squares method using the statsmodels

Abreu & Stone et. al.

467 (<https://www.statsmodels.org/devel/about.html#about-statsmodels>) programming library.
468 Subjects who dropped out of the study or who did not complete a secondary outcome measure
469 were excluded from the analysis. Independent t-tests were performed when comparing adult to
470 pediatric subjects and non-responders to responder subjects. A p -value < 0.05 was considered
471 significant for all analyses. Figures were constructed with matplotlib (<https://matplotlib.org>) and
472 seaborn (<https://seaborn.pydata.org>) programming libraries or GraphPad Prism 8 software
473 (<https://www.graphpad.com/scientific-software/prism/>). Receiver-operator-characteristic (ROC)
474 curves and calculations were constructed using GraphPad Prism 8 software.

Abreu & Stone et. al.

475 **Author contributions**

476 FU designed the study. BAM, NHW, TP, RB, and TH advised on the design of the study. ANS
477 recruited participants and ANS and SH managed the study. TP, RB, JH, LT, SIS, BAM, NHW,
478 and FU examined subjects. SH, CMB, and KK collected the data. CM, DA, SIS, TH, and FU
479 analyzed the data. HG and TH advised on the statistical analysis. DA and SIS wrote the first
480 draft of the manuscript and all the authors revised it critically and approved the final version. DA
481 and SIS are co-first authors.

Abreu & Stone et. al.

482 **Acknowledgements**

483 This work was partly supported by the grants from the National Institutes of Health
484 (NIH)/NIDDK (DK112921, DK113487, DK020579), NIH/ National Center for Advancing
485 Translational Sciences (NCATS) (TR002065, TR000448) and philanthropic supports from the
486 Silberman Fund, the Ellie White Foundation for the Rare Genetic Disorders, the Snow
487 Foundation, the Unravel Wolfram Syndrome Fund, the Stowe Fund, the Eye Hope Foundation,
488 and the Feiock Fund to F. Urano. Research reported in this publication was also supported by the
489 Washington University Institute of Clinical and Translational Sciences grant UL1TR002345
490 from the NIH/NCATS. The content is solely the responsibility of the authors and does not
491 necessarily represent the official view of the NIH. The authors thank all the members of the
492 Washington University Wolfram Syndrome Study and Research Clinic for their support
493 (<https://wolframsyndrome.dom.wustl.edu>) and all the participants in the Wolfram syndrome
494 International Registry and Clinical Study, Research Clinic, and Clinical Trials for their time and
495 efforts. D. Abreu was supported by the NIH training grant (F30DK111070).

Abreu & Stone et. al.

496 **References**

- 497 1. Inoue H, Tanizawa Y, Wasson J, et al. A gene encoding a transmembrane protein is
498 mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). *Nat*
499 *Genet.* 1998;20(2):143-148.
- 500 2. Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. *Current diabetes*
501 *reports.* 2016;16(1):6.
- 502 3. Barrett TG, Bunday SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide
503 study of Wolfram (DIDMOAD) syndrome. *Lancet.* 1995;346(8988):1458-1463.
- 504 4. Urano F. Wolfram syndrome iPS cells: the first human cell model of endoplasmic
505 reticulum disease. *Diabetes.* 2014;63(3):844-846.
- 506 5. Fonseca SG, Ishigaki S, Osowski CM, et al. Wolfram syndrome 1 gene negatively
507 regulates ER stress signaling in rodent and human cells. *The Journal of clinical*
508 *investigation.* 2010;120(3):744-755.
- 509 6. Takei D, Ishihara H, Yamaguchi S, et al. WFS1 protein modulates the free Ca(2+)
510 concentration in the endoplasmic reticulum. *FEBS letters.* 2006;580(24):5635-5640.
- 511 7. Hara T, Mahadevan J, Kanekura K, Hara M, Lu S, Urano F. Calcium Efflux From the
512 Endoplasmic Reticulum Leads to beta-Cell Death. *Endocrinology.* 2014;155(3):758-768.
- 513 8. Lu S, Kanekura K, Hara T, et al. A calcium-dependent protease as a potential therapeutic
514 target for Wolfram syndrome. *Proceedings of the National Academy of Sciences of the*
515 *United States of America.* 2014;111(49):E5292-5301.
- 516 9. Abreu D, Asada R, Revilla JMP, et al. Wolfram syndrome 1 gene regulates pathways
517 maintaining beta-cell health and survival. *Laboratory investigation; a journal of*
518 *technical methods and pathology.* 2020.

Abreu & Stone et. al.

- 519 10. Ellis KO, Castellion AW, Honkomp LJ, Wessels FL, Carpenter JE, Halliday RP.
520 Dantrolene, a direct acting skeletal muscle relaxant. *J Pharm Sci.* 1973;62(6):948-951.
- 521 11. Fruen BR, Mickelson JR, Louis CF. Dantrolene inhibition of sarcoplasmic reticulum
522 Ca²⁺ release by direct and specific action at skeletal muscle ryanodine receptors. *J Biol*
523 *Chem.* 1997;272(43):26965-26971.
- 524 12. Paul-Pletzer K, Palnitkar SS, Jimenez LS, Morimoto H, Parness J. The skeletal muscle
525 ryanodine receptor identified as a molecular target of [3H]azidodantrolene by
526 photoaffinity labeling. *Biochemistry.* 2001;40(2):531-542.
- 527 13. Szentesi P, Collet C, Sarkozi S, et al. Effects of dantrolene on steps of excitation-
528 contraction coupling in mammalian skeletal muscle fibers. *J Gen Physiol.*
529 2001;118(4):355-375.
- 530 14. Otero-Romero S, Sastre-Garriga J, Comi G, et al. Pharmacological management of
531 spasticity in multiple sclerosis: Systematic review and consensus paper. *Mult Scler.*
532 2016;22(11):1386-1396.
- 533 15. Sabouri M, Momeni M, Khorvash F, Rezvani M, Tabesh H. The Effect of a Single dose
534 Dantrolene in Patients with Vasospasm Following Aneurysmal Subarachnoid
535 Hemorrhage. *Adv Biomed Res.* 2017;6:83.
- 536 16. Chen X, Wu J, Lvovskaya S, Herndon E, Supnet C, Bezprozvanny I. Dantrolene is
537 neuroprotective in Huntington's disease transgenic mouse model. *Mol Neurodegener.*
538 2011;6:81.
- 539 17. Bezprozvanny I, Klockgether T. Therapeutic prospects for spinocerebellar ataxia type 2
540 and 3. *Drugs Future.* 2009;34(12).

Abreu & Stone et. al.

- 541 18. Liu J, Tang TS, Tu H, et al. Deranged calcium signaling and neurodegeneration in
542 spinocerebellar ataxia type 2. *J Neurosci*. 2009;29(29):9148-9162.
- 543 19. Shi Y, Wang Y, Wei H. Dantrolene : From Malignant Hyperthermia to Alzheimer's
544 Disease. *CNS Neurol Disord Drug Targets*. 2018.
- 545 20. Wang Y, Shi Y, Wei H. Calcium Dysregulation in Alzheimer's Disease: A Target for
546 New Drug Development. *J Alzheimers Dis Parkinsonism*. 2017;7(5).
- 547 21. Mitani AA, Haneuse S. Small Data Challenges of Studying Rare Diseases. *JAMA Netw*
548 *Open*. 2020;3(3):e201965.
- 549 22. Marshall BA, Permutt MA, Paciorkowski AR, et al. Phenotypic characteristics of early
550 Wolfram syndrome. *Orphanet J Rare Dis*. 2013;8:64.
- 551 23. Hershey T, Lugar HM, Shimony JS, et al. Early Brain Vulnerability in Wolfram
552 Syndrome. *PloS one*. 2012;7(7):e40604.
- 553 24. Marshall BA, Permutt MA, Paciorkowski AR, et al. Phenotypic characteristics of early
554 Wolfram syndrome. *Orphanet journal of rare diseases*. 2013;8(1):64.
- 555 25. Aguilar Bernal OR, Bender MA, Lacy ME. Efficacy of dantrolene sodium in
556 management of tetanus in children. *J R Soc Med*. 1986;79(5):277-281.
- 557 26. Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide:
558 comparison of beta-cell function from OGTT and IVGTT. *Diabetes Res Clin Pract*.
559 2006;72(3):298-301.
- 560 27. Bacha F, Gungor N, Lee S, de las Heras J, Arslanian S. Indices of insulin secretion
561 during a liquid mixed-meal test in obese youth with diabetes. *J Pediatr*. 2013;162(5):924-
562 929.

Abreu & Stone et. al.

- 563 28. Marren SM, Hammersley S, McDonald TJ, et al. Persistent C-peptide is associated with
564 reduced hypoglycaemia but not HbA1c in adults with longstanding Type 1 diabetes:
565 evidence for lack of intensive treatment in UK clinical practice? *Diabet Med*.
566 2019;36(9):1092-1099.
- 567 29. Oram RA, McDonald TJ, Shields BM, et al. Most people with long-duration type 1
568 diabetes in a large population-based study are insulin microsecretors. *Diabetes Care*.
569 2015;38(2):323-328.
- 570 30. Nguyen C, Foster ER, Paciorkowski AR, et al. Reliability and validity of the Wolfram
571 Unified Rating Scale (WURS). *Orphanet journal of rare diseases*. 2012;7:89.
- 572 31. Stone SI, Abreu D, McGill JB, Urano F. Monogenic and syndromic diabetes due to
573 endoplasmic reticulum stress. *Journal of Diabetes and its Complications*. 2020:107618.
- 574 32. Abreu D, Urano F. Current Landscape of Treatments for Wolfram Syndrome. *Trends*
575 *Pharmacol Sci*. 2019;40(10):711-714.
- 576 33. Hoekel J, Chisholm SA, Al-Lozi A, Hershey T, Tychsen L, Washington University
577 Wolfram Study G. Ophthalmologic correlates of disease severity in children and
578 adolescents with Wolfram syndrome. *Journal of AAPOS : the official publication of the*
579 *American Association for Pediatric Ophthalmology and Strabismus / American*
580 *Association for Pediatric Ophthalmology and Strabismus*. 2014;18(5):461-465 e461.
- 581 34. Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people
582 with long-term type 1 diabetes mellitus: the Wisconsin Epidemiologic Study of Diabetic
583 Retinopathy. *Arch Ophthalmol*. 2001;119(5):733-740.
- 584 35. Varni JW, Thompson KL, Hanson V. The Varni/Thompson Pediatric Pain Questionnaire.
585 I. Chronic musculoskeletal pain in juvenile rheumatoid arthritis. *Pain*. 1987;28(1):27-38.

Abreu & Stone et. al.

586 36. Ware JE, Jr. SF-36 health survey update. *Spine (Phila Pa 1976)*. 2000;25(24):3130-3139.

587

588

Abreu & Stone et. al.

589 **Figure Legends**

590 **Figure 1. Trial Design, Enrolment, and Retention.** A) Schematic of 6-month study. Each
591 study visit is noted by a black circle. Study procedures for secondary endpoints are noted in blue.
592 The dose maximization period for dantrolene sodium is noted by the red dashed lines. B)
593 Enrollment and retention diagram for the subjects enrolled in the study. C) Histogram
594 demonstrating distribution of final tolerated dantrolene doses in pediatric subjects at the end of
595 the study. For pediatric subjects this is expressed as mg/kg/day. D) Histogram demonstrating
596 distribution of final tolerated dantrolene doses in adult subjects at the end of the study. For adult
597 subjects this is expressed as mg/day. For both histograms the blue bars represent numbers of
598 subjects taking a dose, red lines represent the exact doses.

599
600 **Figure 2. Secondary study endpoints.** A) Hemoglobin a1c (HbA1c). B) C-peptide during a
601 mixed meal tolerance test. Light boxes represent fasting results, while dark boxes represent 30-
602 minute (stimulated) values. C) LogMAR (a measure of visual acuity). Lower score correlates to
603 more accurate vision. D) Wolfram Unified Rating Scale (WURS) Score. E) Physician rated
604 subsection of the WURS. Higher WURS scores represent more severe disease. All study subjects
605 are broken down into adult and pediatric subgroups. Responders are differentiated from non-
606 responders by having a change in Δ C-peptide ($\Delta\Delta$ C-peptide) ≥ 0.1 ng/mL over the study period
607 (see Figure 3).

608
609 **Figure 3. Subgroup analysis to determine responders vs. non-responders.** A) Δ C-peptide
610 was plotted between all subjects. Then the change in Δ C-peptide ($\Delta\Delta$ C-peptide) was calculated
611 for each subject over the course of the study. Subjects were stratified based on a $\Delta\Delta$ C-peptide $<$

Abreu & Stone et. al.

612 0.05, ≥ 0.05 , ≥ 0.1 , and ≥ 0.2 ng/mL respectively. B) Linear regression analysis demonstrates a
613 significant positive relationship between baseline Δ C-peptide and $\Delta\Delta$ C-peptide. C) Histogram
614 demonstrating the distribution of $\Delta\Delta$ C-peptide in the study population. Solid blue line
615 demonstrates the kernel density estimate. The different cutoff values for $\Delta\Delta$ C-peptide (0.05,
616 0.1, and 0.2 ng/mL) are plotted on both (C) and (D). Based on these analyses a $\Delta\Delta$ C-peptide \geq
617 0.1 ng/mL (depicted in red) was chosen, and these subjects are defined as ‘Responders’
618 throughout the remainder of the analysis.

619

620 **Table 1. Demographic and Clinical Characteristics of the Study Subjects**

621

622 **Table 2. Adverse Events During the Study**

623

Abreu & Stone et. al.

624 **Supplementary Information**

625 **Supplementary Figure 1. Grip strength of each study subject during the study.** A) Right
626 hand B) Left hand.

627
628 **Supplementary Figure 2. C-peptide data from each study subject over the course of the**
629 **study.** Blue represents baseline (fasting) C-peptide. Orange represents 30-minute (stimulated) C-
630 peptide. C-peptide is in ng/mL.

631
632 **Supplementary Figure 3. Predictive value of baseline data.** Histograms plotting A) Basal
633 (fasting) C-peptide, B) Stimulated (30-minute) C-peptide, C) Δ C-peptide, and D) $\Delta\Delta$ C-peptide
634 (as a positive control). Receiver-Operator-Characteristic (ROC) curves were created from these
635 data in order to plot the sensitivity vs. specificity of being a responder based on E) Basal
636 (fasting) C-peptide, F) Stimulated (30-minute) C-peptide, G) Δ C-peptide, and H) $\Delta\Delta$ C-peptide
637 (as a positive control). Area under the curve (AUC) was calculated for each ROC curve. A red
638 dashed line indicates the point with the highest sensitivity and specificity within each ROC
639 curve. This cutoff value is illustrated by a vertical line and annotated on the corresponding
640 histogram.

641
642 **Supplementary Figure 4. Additional markers of β -cell function.** A) Proinsulin collected
643 during a mixed meal tolerance test. B) Insulinogenic Index. C) Area Under the Curve (AUC) C-
644 peptide / AUC Glucose. D) C-peptide to Glucose Ratio All study subjects are broken down into
645 adult and pediatric subgroups. Light boxes represent fasting results, while dark boxes represent
646 30-minute (stimulated) values. Responders are differentiated from non-responders by having a

Abreu & Stone et. al.

647 change in Δ C-peptide ($\Delta\Delta$ C-peptide) \geq 0.1 ng/mL over the course of the study (see
648 Supplementary Figure 3).

649

650 **Supplementary Figure 5. LogMAR visual acuity plot including subject 12.** Subject 12 was
651 excluded from the analysis as they are blind with a LogMar = 3.

652

653 **Supplementary Figure 6. Linear regression analysis.** Linear regression analysis comparing
654 $\Delta\Delta$ C-peptide to (A) LogMAR visual acuity, (B) total WURS, and (C) physician rated WURS.
655 R^2 and p-values are demonstrated in the top right corner of each panel.

656

657 **Supplementary Table S1 . Genetic and Clinical Characteristics of the Study Subjects.**

658

659 **Supplementary Table S2. Secondary Study Endpoints.**

660

661 **Supplementary Table S3. Sensitivity and Specificity**

662 Table based on different cutoff values for Basal C-peptide, Stimulated C-peptide, Δ C-peptide,
663 and $\Delta\Delta$ C-peptide (positive control). Corresponds to Supplementary Figure 3.

664

665 **Supplementary Table S4. Table comparing subgroup analyses at each timepoint.**

666

667 **Supplementary Table S5. Vision-related quality of life by the NEIVFQ-25.**

668

669 **Supplementary Table S6. Pediatric Quality of Life (PedsQL) questionnaire.**

Abreu & Stone et. al.

670

671 **Supplementary Table S7. Physical and mental health metrics as assessed by the SF-36v.**

Figure 1









Figure 2





Characteristic	Pediatric (n = 8)	Adult (n = 11)
Median age (range) - yr	13 (6-17)	23 (18-32)
Female sex -no. (%)	6 (75)	8 (73)
BMI (range) - kg/m ²	20.3 (15.3-29.3)	27.0 (17.8-48.9)
Race - no (%)		
Caucasian	7 (88)	9 (82)
Hispanic or Latino	1 (13)	2 (18)
Median age (range) - yr		
Diabetes mellitus	5 (3-7)	6 (5-14)
Optic Atrophy	7 (5-14)	14 (6-20)
Diabetes insipidus	8 (6-12)	17 (6-26)
Hearing loss	7 (3-16)	8 (2-16)

Table 1. Demographic and Clinical Characteristics of the Study Subjects

Adverse Event: no. (%)	Pediatric	Adult
Dantrolene related		
Fatigue	3 (38)	5 (45)
Diarrhea	2 (25)	3 (27)
Weakness	3 (38)	1 (9)
Dizziness	2 (25)	1 (9)
Elevated Hepatic Enzymes	0 (0)	2 (18)
Nausea	0 (0)	2 (18)
GI upset	1 (13)	1 (9)
Rash	1 (13)	1 (9)
Wolfram related		
Hypoglycemia (mild)	3 (38)	4 (36)
Headaches	2 (25)	4 (36)
Hyponatremia	1 (13)	3 (27)
Hyperglycemia	2 (25)	1 (9)
Urinary tract infection	1 (13)	3 (27)
Hyperkalemia	1 (13)	0 (0)
Urinary retention	1 (13)	0 (0)
Non-specific		
Influenza	1 (13)	1 (9)
Rhinovirus infection	1 (13)	0 (0)
Knee infection	1 (13)	0 (0)
Tics	1 (13)	0 (0)
Knee effusions	0 (0)	1 (9)
Hit by car	0 (0)	1 (9)
Pneumonia	0 (0)	0 (0)
Otitis media	0 (0)	0 (0)

Table 2. Adverse Events During the Study